Undisclosed PROTAC degrader
/ Arvinas, Bayer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 07, 2023
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
- "Submit two investigational new drug (IND)/clinical trial authorization (CTA) applications for the Company’s BCL6 (oncology)...Progress at least two additional PROTAC protein degrader programs into IND- or CTA-enabling studies by year-end 2023....The increase in research and development expenses of $8.4 million for the quarter was primarily due to increases our AR program of $5.2 million, which includes ARV-766 and bavdegalutamide, and our ER program of $6.2 million, which is net of the cost sharing of vepdegestrant under the Vepdegestrant (ARV-471) Collaboration Agreement, offset by a decrease in our platform and exploratory programs of $3.0 million."
Commercial • IND • Oncology
1 to 1
Of
1
Go to page
1